Pharvaris Presents Deucrictibant Clinical Data
Analysis based on 8 articles · First reported May 29, 2026 · Last updated May 29, 2026
The presentation of positive clinical data for Deucrictibant by Pharvaris at a major medical congress could significantly boost investor confidence in Pharvaris, potentially leading to an increase in its stock price. This event highlights the progress in developing new treatments for hereditary angioedema, impacting the biotechnology and pharmaceutical sectors.
Pharvaris, a late-stage biopharmaceutical company, announced the acceptance of one oral presentation and seven flash talk/poster presentations at the European Academy of Allergy and Clinical Immunology Annual Congress 2026 in Istanbul, Turkey, from June 12-15, 2026. The presentations will detail clinical data for Deucrictibant, an oral bradykinin B2 receptor antagonist, for the on-demand treatment of hereditary angioedema (HAE) attacks from the Phase 3 RAPIDe-3 trial, as well as long-term safety and efficacy data for prophylaxis from the Phase 2 CHAPTER-1 open-label extension study. Other presentations include cardiovascular safety assessments, evaluations of Deucrictibant extended-release and immediate-release combinations, a kinin biomarker assay, and patient insights from the RAPIDe-3 study. This event is crucial for Pharvaris as it showcases the progress and potential of Deucrictibant in addressing unmet needs in bradykinin-mediated conditions.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard